<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950466</url>
  </required_header>
  <id_info>
    <org_study_id>PI 084-2016</org_study_id>
    <secondary_id>STGRA17049OSASPAEDS-SH</secondary_id>
    <nct_id>NCT03950466</nct_id>
  </id_info>
  <brief_title>Real Life Pediatric Obstructive Sleep Apnea</brief_title>
  <acronym>RELIPOSA</acronym>
  <official_title>OBSTRUCTIVE SLEEP APNEA SYNDROME IN CHILDREN: HEALTH AND NEUROCOGNITIVE IMPACT. Real Life Pediatric Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      PRIMARY: To analyze the cognitive alterations in children with Obstructive Sleep Apnea OSA in
      different age groups and changes at 12 months after treatment with a protocol based on usual
      clinical practice.

      DESIGN:

      Observational, longitudinal, prospective, and multicenter study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY POPULATION: Children aged 3 to 12 years consecutively referred to the Sleep Units due
      to clinical suspicion of OSA.

      SAMPLE SIZE: To evaluate the relationship between cognitive measures and polysomnographic
      variables and differences before-after treatment, a sample size of 1200 children is
      calculated.

      METHODOLOGY: The followiong will be obtained in all children included in the study: personal
      medical history, Spanish version of Pediatric Sleep Questionnaire (PSQ), physical and
      otorhinolaryngological examination, neurocognitive assessment by customary neurocognitive and
      behavioral tests routinely used in Spain (CUMANIN neuropsychological tests, ENFEN
      neuropsychological tests, and Spanish version of the ECBI (Eyberg Child Behavior Inventory)),
      sleep study by polysomnography (PSG) or Respiratory Polygraphy (PR) and blood test.

      The diagnosis and treatment of OSAS will be established according to the criteria of the
      Spanish Consensus Document of OSAS in children.

      Depending on the treatment, three groups will be obtained: Group 1: Children with OSAS and
      adenotonsillar hypertrophy we will perform surgical treatment. Group 2: Children with OSAS
      and without adenotonsillar hypertrophy will be evaluated other treatments (sleep hygiene-diet
      and physical activity guidance, medical, orthodontic, continuous positive pressure on the
      airway (CPAP) treatment, Group 3: regular follow up but no treatment for children referred
      for suspicion of OSAS and that in PSG or RP the diagnosis of OSAS is not established. In all
      three groups, at 12 months, we will repeat all assessments as delineated for the initial
      visit
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive changes after treatment in children with Obstructive Sleep Apnea (OSA)</measure>
    <time_frame>2018-2021</time_frame>
    <description>Changes from before treatment in neurocognitive score on CUMANIN neuropsychological tests in chilren under 6 years old or ENFEN neuropsychological tests in children over six years old at 1 year after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavior changes after treatment in children with Obstructive Sleep Apnea (OSA)</measure>
    <time_frame>2018-2021</time_frame>
    <description>Changes from before treatment in behavior score on ECBI (Eyberg Child Behavior Inventory) at 1 year after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep changes after treatment in children with Obstructive Sleep Apnea(OSA)</measure>
    <time_frame>2018-2021</time_frame>
    <description>Changes from baseline in sleep study on polysomnography after treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <condition>Children</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children from 3 to 12 years-old referred consecutively to the Sleep Units of the
        participating sites due to clinical suspicion of OSA.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 3 to 12 years consecutively referred to the Sleep Units due to clinical
             suspicion of OSA.

        Exclusion Criteria:

          -  A significant medical and/or psychiatric comorbidity that may require urgent treatment
             (Respiratory Failure, Heart Failure, Cardiac Malformations, tumors, psychiatric type
             disorders that may require specific treatment…)

          -  Craniofacial malformations, deposit diseases and/or malformation syndromes (including
             Down's syndrome)

          -  Already diagnosed neurocognitive type disorders (e.g.: Autism, cerebral palsy, etc.)

          -  Attention deficit hyperactivity disorders previously diagnosed according to DSM-IV
             criteria

          -  Girls ≤ 12 with menarche at the time of starting the study

          -  Children that refuse to take part in the study (do not sign the Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>María Luz Alonso-Alvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial Universitario de Burgos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Luz Alonso-Alvarez, MD</last_name>
    <phone>34 610246473</phone>
    <email>mlalonso@hubu.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joaquin Terán-Santos, MD</last_name>
    <phone>34 630028489</phone>
    <email>jtjteran07@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Luz Alonso-Alvarez, MD</last_name>
      <phone>34610246473</phone>
      <email>mlalonso@hgy.es</email>
    </contact>
    <investigator>
      <last_name>Maria Luz Alonso-Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Luz Alonso-Alvarez, MD</last_name>
      <phone>34 610246473</phone>
      <email>mlalonso@hubu.es</email>
    </contact>
    <contact_backup>
      <last_name>Joaquin Terán-Santos, MD</last_name>
      <phone>34 630028489</phone>
      <email>jtjteran07@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>ML Alonso-Alvarez</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Sleep apnea</keyword>
  <keyword>Children</keyword>
  <keyword>Neurocognitive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

